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Abstract: (Trimethylsilyl)diazomethane (TMS-CHN2) reacts smoothly with cycloaliphatic thioketones as
well as with fluorene-9-thione at low temperature to give the corresponding 1,3,4-thiadiazole derivatives as
product of a regioselective [3+2]-cycloaddition. In the first case, the obtained cycloadducts are relatively
stable and eliminate N2 upon heating at 40ºC. In the second case, N2-extrusion occurs already at –40ºC.
The silylated thiocarbonyl S-methanides generated thereby can be trapped regioselectively with ferro-
cenyl hetaryl thioketones to give the sterically crowded 2-silylated 4,4,5,5-tetrasubstituted 1,3-dithiolanes.
Without isolation, these products are desilylated with TBAF and tetrasubstituted ethenes or dibenzo-
fulvenes are obtained as final products via cycloelimination (‘[3+2]-cycloreversion’) of the intermediate
1,3-dithiolane carbanion.
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Programmed death receptor 1 (PD1) has been identified 
as critical negative regulator of T cell activity (1). While 
PD1-mediated T cell inhibition is an important mechanism 
to prevent autoimmunity, cancer and chronic infectious 
diseases may usurp this regulation mechanism to drive 
immune suppression (2). In fact, the PD1-PD-L1 axis 
is one of the major axis used by a variety of cancer types 
to inhibit T cell responses and function (3). As a direct 
consequence, strategies interfering with PD1-signaling such 
as antibodies have entered the clinic and are approved in a 
number of indications (4). A remarkable aspect being that 
these so-called check point inhibitors also show significant 
activity in such clinical situations where any other therapy 
had previously failed (5). PD1-blocking agents are under 
investigation in almost every cancer indication and the 
approved fields for therapy are constantly increasing (4). 
A major limitation is to differentiate patients who will 
benefit from this therapy from those who will not. Current 
strategies such as ligand expression in the tumor tissue, 
however, fail to reliably predict outcome, calling for 
additional research for patient stratification (6-8). Owing 
to the huge medical and economical impact disruption of 
the PD1-PD-L1 interactions has, a better understanding 
of PD1 biology and the identification of appropriate 
biomarkers emerge as a priority.
PD1 is part of a larger family of receptors and surface 
molecules: the CD28 superfamily of receptors (9). 
Early work on PD1 and other related receptors could 
demonstrate that their signaling motives are compatible and 
could be swapped to exchange the functions of the receptors 
(10,11). CD28 can be turned into a suppressive molecule, if 
intracellular PD1 is fused to its C-terminus. Vice-versa, this 
compatibility can also be employed therapeutically, as PD1 
can be fused to the CD28 signaling motives to generate a 
switch turning PD1 suppression into CD28 costimulation 
(12-14). Introducing such a PD1-CD28 switch in antigen-
specific T cells can break suppression and enhance 
therapeutic T cell efficacy against tumors. It seems that 
this strategy can be employed both for TCR and chimeric 
antigen receptor transduced T cells. Such data demonstrates 
the value of simultaneous protection from PD1 inhibition 
and CD28 costimulation when the T cell meets its target.
A recent publication from Kamphorst and colleagues 
released in Science now demonstrated that CD28 on 
the T cell side and B7 on the tumor-bearing host side 
are necessary for full activity of PD1-blockade (15). 
Mechanistically, CD28 is required for adequate T cell 
proliferation upon PD1-antibody blockade and ultimately 
rescue of an exhausted phenotype and restoration of T cell 
effector function. The authors proved their hypothesis first 
in the LCMV chronic infection model and in the CT26 
colon cancer model using different genetic deletion models 
for CD28 and blocking antibodies. In patients suffering 
from NSCLC receiving PD1-blockade in therapeutic 
intention, the authors found that PD1+ T cells responding 
through proliferation expressed CD28. They argue that 
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this finding corroborates the clinical relevance of their 
observations.
These results are remarkable on three levels (Figure 1): 
first, they imply that costimulation must be present for 
PD1-blockade activity. In other words, T cells must have 
already broken inertia and taken up speed through different 
layers of stimulation (signal one and two) for PD-1 to 
exert its full suppressive activity. It appears surprising and 
somehow counterintuitive as our text book knowledge 
argues that PD1-PD-L1 interactions happen at the effector 
site of a tumor or infected tissue where CD8+ T cells meet 
their antigen in the context of MHC and drive anergy (16). 
These novel insights now mean that costimulation through 
B7-molecules, probably coming from antigen presenting 
cells as main B7 expressors, must take place before T cell 
anergy can occur. Another possibility is simultaneous 
expression of B7 and PD-L1 on the tumor cell, which 
however, appears less likely as most cancer entities do 
not express costimulatory molecules. An unanswered 
question is whether costimulation and suppression must 
happen simultaneously and at the same site or if sequential 
binding would result in the same biological effect. Such 
consideration is important, as it would guide future work 
for the search of biomarkers and therapeutic applications.
Second, PD1 must somehow interfere with CD28 
signaling or activity. Such consideration is unaddressed 
in the manuscript but would provide a more detailed 
mechanistical explanation to the observed findings. 
Figure 1 Prior activation is a pre-requisite for clinically relevant blockade of the PD1-PD-L1 axis. Recent studies by Kamphorst et al. 
and Hui et al. suggest that only after co-stimulation through CD28 engagement via B7 molecules on APCs, subsequent blockade of PD-1 
(or its ligand PD-L1 on tumor cells or associated stroma cells or APCs) can lead to clinical benefit (light green, upper panels). In absence 
of costimulation, inert T cells do not react to PD1-PD-L1 pathway blockade (grey, lower panels). APC, antigen presenting cell; PD1, 
programmed death-1; PD-L1, PD1-ligand.
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Again, our previous knowledge makes the point that 
downstream TCR signaling is the main target for PD1 
dephosphorylation activity (17). This assumption is 
corroborated by a publication by Hui et al. who have 
conducted a detailed biochemical analysis of the targets 
for dephosphorylation activity of PD1(18). Remarkably, 
they found that unlike previously demonstrated the major 
targets are the tyrosine motives of CD28, providing direct 
evidence for the functional findings of Kamphorst et al. It 
would be of major interest to now understand the kinetics 
of the interactions: can dephosphorylation still occur if PD1 
engagement was prior to CD28 activation? How long does 
the dephosphorylation last and can this effect be overrun by 
an excess of either signal? Such considerations might have a 
direct impact on the design of future therapies.
Third, the interplay between PD1 and CD28 might 
provide the long thought after reasoning on why PD-L1 
expression does not predict response to PD1 blockade. The 
field has long been hoped for PD-L1 as a biomarker for 
PD1-blockade activity but controversial and inconsistent 
clinical data have proven its limitations (19). If the findings 
outlined by Kamphorst and colleagues hold true in a clinical 
setting, the requirement for B7 molecules might provide 
a direct explanation for the lack of predictive value of PD-
L1 expression. It then appears likely that either molecule 
might be limiting for the impact of PD1-mediated T cell 
inhibition. Thus, if B7 is not present PD1 might not be a 
major driver of T cell anergy in a given patient and vice 
versa, if PD-L1 is not present or not where required, 
costimulation might not be the target of anergy and other 
mechanisms will kick in. However, several issues remain 
unaddressed: where do PD-L1 and B7 need to be expressed 
for PD1-mediated T cell suppression and to which degree? 
Is it sufficient if neighboring cells express either of them? Is 
simultaneous expression on the same cell necessary? These 
are questions that among others will need to be interrogated 
to further explore this clinical avenue.
In summary, the study by Kamphorst and coworkers 
have discovered a novel major mechanism used by PD1 
to induce T cell anergy and required for PD1-blockade 
activity. Their study opens a new avenue of investigation if 
the mode of action of PD1 and on how this will be used to 
enhance the activity of immunotherapies and better predict 
their outcome.
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